S'abonner

Effect of the staging schema on melanoma cancer reporting, 1999 to 2006 - 20/10/11

Doi : 10.1016/j.jaad.2011.04.034 
Sue-Min Lai, PhD, MS, MBA a, , Jessica B. King, MPH b, Sarma Garimella, MBBS, MPH a, John Keighley, PhD a, Mary Lewis, CTR, RHIT b
a Kansas Cancer Registry, University of Kansas Medical Center, Kansas City, Kansas 
b Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 

Reprint requests: Sue-Min Lai, PhD, MS, MBA, Department of Preventive Medicine and Public Health, University of Kansas Medical Center, Mail Stop 1008, 3901 Rainbow Blvd, Kansas City, KS 66160.

Abstract

Background

Staging schemas have changed multiple times over the past 10 years.

Objective

We sought to examine the impact of staging schemas on the distribution of stages at diagnosis over time.

Methods

We examined the stage at diagnosis for melanoma cancer cases diagnosed between 1999 and 2006 using data provided by the Surveillance, Epidemiology, and End Results (SEER) and National Program of Cancer Registries (NPCR) programs. The staging schemas were summary staging 1977 (SS1977), summary staging 2000 (SS2000), derived SS2000, and SEER historic staging systems.

Results

Melanoma was predominantly staged as a localized disease in all schemas. Using SEER data, the proportion of localized melanomas diagnosed in 2001 to 2003 using SS2000 was about 2.5% lower than the proportion diagnosed in 1999 to 2000 using SS1977, whereas the proportion of cases staged as regional was 2.7% higher using the SS2000 than SS1977. The distribution of stages for cases diagnosed in 2001 to 2003 using SS2000 was similar to that for cases diagnosed in 2004 to 2006 using a derived SS2000. Shift in stage distribution among SS1977, SS2000, and SEER historic staging was found to be about 6% (localized to regional) and about 17.5% (unknown to regional stage). The distribution of changes in stage observed for the SEER cases was not evident for cases from NPCR.

Limitations

SEER historic staging was not available for NPCR cases.

Conclusion

Changes in staging rules resulted in cases being moved from the localized to the regional stage and from unknown to the regional stage. Without staging rules that have been consistently applied to melanomas over many years, surveillance of prevention, treatment, and control of this condition is difficult.

Le texte complet de cet article est disponible en PDF.

Key words : derived summary staging 2000, malignant melanoma, stages at diagnosis, summary staging 1977, summary staging 2000, Surveillance, Epidemiology, and End Results historic staging

Abbreviations used : derived SS2000, NPCR, SEER, SHSS, SS1977, SS2000


Plan


 Publication of this supplement to the JAAD was supported by the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC).
 Conflicts of interest: None declared.
 The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions, recommendations, or official position of the journal editors or the Centers for Disease Control and Prevention.


© 2011  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 65 - N° 5S1

P. S95.e1-S95.e10 - novembre 2011 Retour au numéro
Article précédent Article précédent
  • Reducing mortality in individuals at high risk for advanced melanoma through education and screening
  • Alan C. Geller, Susan M. Swetter, Susan Oliveria, Stephen Dusza, Allan C. Halpern
| Article suivant Article suivant
  • Targeting children through school-based education and policy strategies: Comprehensive cancer control activities in melanoma prevention
  • Julie S. Townsend, Beth Pinkerton, Sharon A. McKenna, Sue M. Higgins, Eric Tai, C. Brooke Steele, Susan R. Derrick, Christine Brown

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.